Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4794398 | 0.99 | HCRTR1 (0.41) | HCRTR1RAB9ANPC1SMN1; SMN2KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4777187 | 0.92 | HCRTR1 (0.39) | HCRTR1RAB9ANPC1SMN1; SMN2KCNH2 | |
| SCHEMBL27238873 | 0.90 | HCRTR1 (0.40) | HCRTR1RAB9ANPC1SMN1; SMN2CYP2C19 | |
| SCHEMBL3975080 | 0.87 | RAB9A (0.42) | HCRTR1RAB9ANPC1SMN1; SMN2KCNH2 | |
| SCHEMBL26167918 | 0.85 | LMNA (0.38) | HCRTR1RAB9ANPC1SMN1; SMN2EGFR | |
| SCHEMBL16572849 | 0.85 | HCRTR1 (0.37) | HCRTR1RAB9ANPC1SMN1; SMN2KCNH2 | |
| SCHEMBL1252616 | 0.84 | CYP2C19 (0.43) | CYP2C19KMT2A | |
| SCHEMBL15999427 | 0.84 | PKM (0.38) | RAB9ANPC1KMT2AL3MBTL1PKM | |
| SCHEMBL15999473 | 0.84 | PKM (0.48) | RAB9ANPC1KCNH2KMT2AL3MBTL1 | |
| SCHEMBL23532095 | 0.83 | SLC22A12 (0.42) | RAB9ASMN1; SMN2CYP2C19KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | claimed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | claimed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | claimed |
| EP-1973902-A2 | 3-HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2008-10-01 | — | — | EP | claimed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | claimed |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025078209-A1 | ANTIBIOTIC COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-17 | — | — | WO | disclosed |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-12-31 | — | — | US | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007053131-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-05-10 | — | — | WO | disclosed |
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-08-17 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1575951-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | Affinium Pharmaceuticals, Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004052890-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AADAC, AZI2, DCXR | HCRTR1 4418/4885RAB9A 4371/4885NPC1 4765/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | HCRTR1 2025/4885RAB9A 345/4885NPC1 389/4885 |
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | RPSA, RPS5, RPS2 | HCRTR1 4760/4885RAB9A 1428/4885NPC1 4367/4885 |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | RPSA, RPS5, RPS2 | HCRTR1 4760/4885RAB9A 1428/4885NPC1 4367/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | HCRTR1 4634/4885RAB9A 2755/4885NPC1 317/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | HCRTR1 4706/4885RAB9A 1576/4885NPC1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.